Vinay Prasad has returned to the Food and Drug Administration (FDA) to resume leadership of its Center for Biologics Evaluation and Research (CBER), weeks after an abrupt departure linked to internal tensions. This surprising reinstatement comes at the agency's request, highlighting ongoing leadership challenges within the office overseeing vaccines, gene therapies, and blood products. HHS spokesperson Andrew Nixon confirmed Prasad's return, but details about his broader role remain unclear amid a backdrop of political controversy and staff concerns involving public expert meetings and panel transparency.